Posted by Michael Wonder on 26 Jun 2024
UCB’s epilepsy drug Briviant (brivaracetam) approved in Japan for treatment of focal onset seizures
26 June 2024 - Approval is supported by positive results from a Phase 3 clinical study which evaluated the efficacy and safety of adjunctive brivaracetam in participants with focal-onset seizures across the Asia-Pacific region.
UCB today announced that the Japanese MHLW has granted marketing authorisation for Briviact (brivaracetam) as monotherapy and adjunctive therapy in the treatment of partial onset seizures of epilepsy patients with or without secondary generalisation in adult patients with epilepsy.
